NOVAVAX INC Operating Lease Liability
NOVAVAX INC (NVAX) had Operating Lease Liability of $29.24 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-02-26
- 2025-12-31: Operating Lease, Liability $29.24M.
- 2024-12-31: Operating Lease, Liability $33.05M.
- 2023-12-31: Operating Lease, Liability $112.62M.
- 2022-12-31: Operating Lease, Liability $125.39M.
| Period end | Operating Lease, Liability |
|---|---|
| 2025-12-31 | $29.24M 10-K · filed 2026-02-26 |
| 2024-12-31 | $33.05M 10-K · filed 2025-02-27 |
| 2023-12-31 | $112.62M 10-K · filed 2024-02-28 |
| 2022-12-31 | $125.39M 10-K · filed 2023-02-28 |
| 2021-12-31 | $200.63M 10-K · filed 2022-03-01 |
| 2020-12-31 | $159.85M 10-K · filed 2021-03-01 |
| 2020-09-30 | $3.87M 10-Q · filed 2020-11-10 |
| 2019-12-31 | $11.27M 10-K · filed 2020-03-11 |
| 2019-09-30 | $11.44M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $24.70M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $20.89M 10-Q · filed 2019-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |